Evaluation of long-term safety and effectiveness of fostamatinib in the treatment of rheumatoid arthritis (RA) - OSKIRA-X

Study identifier:D4300C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:2010-020892-22

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis

Medical condition

Rheumatoid Arthritis

Phase

Phase 3

Healthy volunteers

No

Study drug

Fostamatinib

Sex

All

Actual Enrollment

1917

Study type

Interventional

Age

18 Years - 150 Years

Date

Study Start Date: 01 Jan 2011
Primary Completion Date: 01 Jun 2013
Study Completion Date: 01 Sept 2013

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria